These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20121288)

  • 1. Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China.
    Xu S; Li J; Bao Z; Xing H; Zhong P; Li H; Zhou H; Li X; Wu S; Song A; Li X; Nie J; Wang Y
    Mol Diagn Ther; 2010 Feb; 14(1):31-41. PubMed ID: 20121288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China].
    Si XF; Huang HL; Wei M; Guan Q; Song YH; Ma PF; Quan Y; Xing H; Shao YM
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Dec; 18(4):308-11. PubMed ID: 15650776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors.
    Peduzzi C; Pierotti P; Venturi G; Romano L; Mazzotta F; Zazzi M
    J Clin Virol; 2002 Jul; 25(1):57-62. PubMed ID: 12126722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
    Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
    Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia.
    Huruy K; Maier M; Mulu A; Liebert UG
    J Med Virol; 2015 Jun; 87(6):978-84. PubMed ID: 25649964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 genotypic resistance profile of patients failing antiretroviral therapy in Paraná, Brazil.
    Toledo PV; Carvalho DS; Romagnoli L; Marcinko G; Cunha CA; Souza MN; Brindeiro R; Queiroz-Telles Fd
    Braz J Infect Dis; 2010; 14(4):360-71. PubMed ID: 20963321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
    Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations associated with genotypic resistance to antiretroviral therapy in treatment naïve HIV-1 infected patients in Greece.
    Magiorkinis E; Paraskevis D; Magiorkinis G; Chryssou S; Chini M; Lazanas M; Paparizos V; Saroglou G; Antoniadou A; Giamarellou E; Karafoulidou A; Hatzakis A
    Virus Res; 2002 Apr; 85(1):109-15. PubMed ID: 11955643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
    Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Drug Resistance Profiles for the HIV Protease and Reverse Transcriptase Gene in Patients Receiving Combination Therapy in Tehran, Iran.
    Sadeghi L; Lolaie M; Tabatabai RA; Bayanolhagh S; Taj L; Ahmadi NE; Abedinzadeh N; Vakili F; Ahmadi G; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):241-248. PubMed ID: 29663899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.
    Lee JH; Hachiya A; Shin SK; Lee J; Gatanaga H; Oka S; Kirby KA; Ong YT; Sarafianos SG; Folk WR; Yoo W; Hong SP; Kim SO
    Clin Microbiol Infect; 2013 Jun; 19(6):E263-70. PubMed ID: 23480551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The infection staging and profile of genotypic distribution and drug resistance mutation among the human immunodeficiency virus-1 infected blood donors from five Chinese blood centers, 2012-2014.
    Zeng P; Liu Y; He M; Wang J; Keating S; Mao W; Huang M; Ma H; He W; Bi X; Liao D; Busch M; Ness P; Liu J; Shan H;
    PLoS One; 2017; 12(6):e0179328. PubMed ID: 28622345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary resistance of HIV to antiretrovirals among individuals recently diagnosed at voluntary counselling and testing centres in the metropolitan region of Recife, Pernambuco.
    Cavalcanti AM; Brito AM; Salustiano DM; Lima KO; Silva SP; Diaz RS; Lacerda HR
    Mem Inst Oswaldo Cruz; 2012 Jun; 107(4):450-7. PubMed ID: 22666853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2014 Mar; 65(3):318-26. PubMed ID: 24525469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
    Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
    Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic resistance of antiretroviral drugs among drug-naive HIV type 1 patients with the background of long-term access-easy zidovudine therapy.
    Park SW; Kim HB; Choi YJ; Kim NJ; Oh MD; Choe KW
    AIDS Res Hum Retroviruses; 2003 Nov; 19(11):1039-43. PubMed ID: 14686324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain.
    Gallego O; Ruiz L; Vallejo A; Ferrer E; Rubio A; Clotet B; Leal M; Soriano V;
    AIDS; 2001 Sep; 15(14):1894-6. PubMed ID: 11579258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.